These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31619029)

  • 1. Risk of Gleason Score 3+4=7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy.
    De Luca S; Fiori C; Bollito E; Garrou D; Aimar R; Cattaneo G; De Cillis S; Manfredi M; Tota D; Federica M; Passera R; Porpiglia F
    Minerva Urol Nefrol; 2020 Jun; 72(3):360-368. PubMed ID: 31619029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Porpiglia F; DE Luca S; Passera R; Manfredi M; Mele F; Bollito E; DE Pascale A; Cossu M; Aimar R; Veltri A
    Anticancer Res; 2016 Sep; 36(9):4833-9. PubMed ID: 27630337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy for Quantitative Gleason 4 Grading Prediction in Radical Prostatectomy Specimens: Implications for Active Surveillance Candidate Selection.
    Kachanov M; Budäus L; Beyersdorff D; Karakiewicz PI; Tian Z; Falkenbach F; Tilki D; Maurer T; Sauter G; Graefen M; Leyh-Bannurah SR
    Eur Urol Focus; 2023 Mar; 9(2):303-308. PubMed ID: 36184537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
    Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
    Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
    Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
    Urology; 2023 May; 175():151-156. PubMed ID: 36828261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
    Kim H; Kim JK; Hong SK; Jeong CW; Ku JH; Kwak C
    World J Urol; 2021 Jun; 39(6):1825-1830. PubMed ID: 32869150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of TRUS and combined MRI-targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology.
    Aslan G; Çelik S; Sözen S; Akdoğan B; İzol V; Yücel Bilen C; Sahin B; Türkeri L;
    Int J Clin Pract; 2021 Mar; 75(3):e13797. PubMed ID: 33113261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer.
    Porpiglia F; DE Luca S; Checcucci E; Garrou D; Manfredi M; Mele F; Pecoraro A; Passera R; Bollito E; Fiori C
    Anticancer Res; 2018 May; 38(5):3043-3047. PubMed ID: 29715138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.
    Mannaerts CK; Kajtazovic A; Lodeizen OAP; Gayet M; Engelbrecht MRW; Jager GJ; Wijkstra H; de Reijke TM; Beerlage HP
    Urol Oncol; 2019 May; 37(5):298.e1-298.e9. PubMed ID: 30660493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
    Huang CC; Kong MX; Zhou M; Rosenkrantz AB; Taneja SS; Melamed J; Deng FM
    Am J Surg Pathol; 2014 Aug; 38(8):1096-101. PubMed ID: 24832163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.
    Fourcade A; Payrard C; Tissot V; Perrouin-Verbe MA; Demany N; Serey-Effeil S; Callerot P; Coquet JB; Doucet L; Deruelle C; Joulin V; Nonent M; Fournier G; Valeri A
    Scand J Urol; 2018 Jun; 52(3):174-179. PubMed ID: 29463177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.
    Mannaerts CK; Engelbrecht MRW; Postema AW; van Kollenburg RAA; Hoeks CMA; Savci-Heijink CD; Van Sloun RJG; Wildeboer RR; De Reijke TM; Mischi M; Wijkstra H
    BJU Int; 2020 Oct; 126(4):481-493. PubMed ID: 32315112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies.
    Zhao Y; Deng FM; Huang H; Lee P; Lepor H; Rosenkrantz AB; Taneja S; Melamed J; Zhou M
    Arch Pathol Lab Med; 2019 Jan; 143(1):86-91. PubMed ID: 29965785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis.
    Goel S; Shoag JE; Gross MD; Al Hussein Al Awamlh B; Robinson B; Khani F; Baltich Nelson B; Margolis DJ; Hu JC
    Eur Urol Oncol; 2020 Feb; 3(1):10-20. PubMed ID: 31492650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups.
    Ozkaya M; Simsekoglu MF; Kalender G; Sahin KC; Gurses I
    Prostate; 2024 Sep; 84(12):1146-1156. PubMed ID: 38798171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
    BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.